


## L-3,5,3'-[<sup>125</sup>I]-Triiodothyronine

### [<sup>125</sup>I]-T<sub>3</sub>

Product Number: NEX110H



#### LOT SPECIFIC INFORMATION:

CALCULATED AS OF: 15-Jan-2024

LOT NUMBER: AR22340

SPECIFIC ACTIVITY: 28.8 TBq/mmol  
779 Ci/mmol  
44.4 MBq/μg  
1200 μCi/μg

CONCENTRATION: 12.8 MBq/ml  
346 μCi/ml

#### Package Size Information

Package Size as of 23-Feb-2024	Volume
3.70 MBq 100 μCi	0.50 ml
9.25 MBq 250 μCi	1.25 ml
18.5 MBq 500 μCi	2.50 ml

RADIOCHEMICAL PURITY: ≥ 95%

MOLECULAR WEIGHT: 649

PACKAGING: L-3,5,3'-[<sup>125</sup>I]-Triiodothyronine is in a solution containing 1-propanol:water, 1:1. It is shipped ambient.

SPECIAL INFORMATION: This compound is light sensitive. Exposure to light may hasten decomposition. L-3,5,3'-[<sup>125</sup>I]-Triiodothyronine is supplied in a red NENSURE™ vial which contains a U.V. inhibitor.

STABILITY AND STORAGE: L-3,5,3'-[<sup>125</sup>I]-Triiodothyronine should be stored at 4°C or lower in the dark. Under these conditions the product is stable and usable for at least six weeks after fresh lot date.

SPECIFIC ACTIVITY: ~1200 μCi/μg (~44 MBq/μg) on fresh lot date. This is obtained by dilution of no carrier added

RADIOCHEMICAL PURITY: Initially greater than 95% radiochemically pure as determined by HPLC. [<sup>125</sup>I]-T<sub>3</sub> with unlabeled T<sub>3</sub>. Specific activity decays with time.

**PREPARATIVE PROCEDURE:** L-3,5-Diiodothyronine is radioiodinated with no carrier added <sup>125</sup>I using a modification of the Hunter and Greenwood method<sup>1</sup> and is purified by reversed phase HPLC.

**AVAILABILITY:** L-3,5,3'-[<sup>125</sup>I]-Triiodothyronine is routinely available from stock and is prepared fresh and packaged for shipment on the third Monday of each month. Please inquire for larger package sizes.

**HAZARD WARNING:** This product contains a chemical(s) known to the state of California to cause cancer. This product also contains a component which is harmful by contact, ingestion or inhalation. It is irritating to the eyes, skin and respiratory tract. It is toxic and flammable. Target organs are the eyes, central nervous system, kidneys and the liver.

**RADIATION UNSHIELDED:** 280mR/hr/mCi at vial surface.

**REFERENCES:**

1. Hunter, W.M., and F.C. Greenwood, *Nature* 194, 495 (1962).

**IODINE-125 DECAY CHART HALF LIFE=60 days**

**Radiations:** Gamma 35.5 keV (7%) , X-ray K alpha 27 KeV (112%), K beta 31 keV (24%)

DAYS	0	2	4	6	8	10	12	14	16	18
0	1.000	.977	.955	.933	.912	.891	.871	.851	.831	.812
20	.794	.776	.758	.741	.724	.707	.691	.675	.660	.645
40	.630	.616	.602	.588	.574	.561	.548	.536	.524	.512
60	.500	.489	.477	.467	.456	.445	.435	.425	.416	.406
80	.397	.388	.379	.370	.362	.354	.345	.338	.330	.322
100	.315	.308	.301	.294	.287	.281	.274	.268	.262	.256
120	.250	.244	.239	.233	.228	.223	.218	.213	.208	.203

To obtain the correct radioactive concentration or amount for a date before the calibration date: divide by the decay factor corresponding to the number of days before the calibration date. To obtain the correct radioactive concentration or amount for a date after the calibration date: multiply by the decay factor corresponding to the number of days after the calibration date.

The information provided in this document is valid for the specified lot number and date of analysis. This information is for reference purposes only and does not constitute a warranty or guarantee of the product's suitability for any specific use. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume any liability for any errors or damages arising from the use of this document or the product described herein. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF.

